A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status.

Failure to make findings of fact adds twist to battle over Eliquis in Ireland ...

"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

A patient who went to the hospital in Thompson, Man., for urgent care to his leg is suing the doctor who treated him, after ...

This tea tea been used as a remedy for nausea, but its uses could go far beyond this as it is thought to have antioxidant and ...

This tea tea been used as a remedy for nausea, but its uses could go far beyond this as it is thought to have antioxidant and anti-inflammatory properties ...

Bristol Myers Squibb and Pfizer’s oral anticoagulant Eliquis is the stronger competitor. Despite being approved more than a decade ago, Eliquis’ market presence continues to grow, surging 9% ...

This approach has recently been challenged by TIMING 2 and ELAN, 3 two large randomized trials in which early direct oral anticoagulant (DOAC) therapy appeared to be safe in most patients with ...

There are valid reasons for the apprehension: Pfizer faces patent expirations soon on multiple drugs, including Eliquis, Vyndaqel, Xeljanz, Ibrance, and Xtandi. That could total an $18 billion hit ...

The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to the full-dose regimen in preventing recurrent venous thromboembolism in ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...